430 related articles for article (PubMed ID: 29131379)
1. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
4. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Khedr F; Ibrahim MK; Eissa IH; Abulkhair HS; El-Adl K
Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100201. PubMed ID: 34411344
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100278. PubMed ID: 34596910
[TBL] [Abstract][Full Text] [Related]
6. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
7. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
8. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
13. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
15. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
16. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Abou-Seri SM; Eldehna WM; Ali MM; Abou El Ella DA
Eur J Med Chem; 2016 Jan; 107():165-79. PubMed ID: 26590508
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
20. Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.
Amin KM; Barsoum FF; Awadallah FM; Mohamed NE
Eur J Med Chem; 2016 Nov; 123():191-201. PubMed ID: 27484508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]